John Reagan
Brown University Oncology Research Group (BrUOG)
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name John Reagan as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 00:04 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT03374332 · Fractionated Gemtuzumab Ozogamicin Followed by Non-engraftment Donor Leukocyte Infusions for Relapsed/Refractory Acute Myeloid LeukemiaBrown University · completed · Acute Myeloid Leukemia · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 00:04 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 00:04 UTC. The ranking covers the 200 most relevant of 13 PubMed records, and a shared surname and initials can bring in a namesake. All 13 on PubMed
- Addition of alendronate to ongoing hormone replacement therapy in the treatment of osteoporosis: a randomized, controlled clinical trial.J Clin Endocrinol Metab · 1999129 citationsRCR 4.0
- Bortezomib plus EPOCH is effective as frontline treatment in patients with plasmablastic lymphoma.Br J Haematol · 201978 citationsRCR 3.4
- Leukotrienes in ulcerative colitis: results of a multicenter trial of a leukotriene biosynthesis inhibitor, MK-591.Gastroenterology · 199763 citationsRCR 1.6
- Time to treatment is an independent prognostic factor in aggressive non-Hodgkin lymphomas.Br J Haematol · 201837 citationsRCR 1.3
- 29 citationsRCR 2.0
- Cellular immunotherapy for refractory hematological malignancies.J Transl Med · 201328 citationsRCR 0.8
- Acid suppression by famotidine 20 mg twice daily or 40 mg twice daily in preventing relapse of endoscopic recurrence of erosive esophagitis.Clin Ther · 199512 citationsRCR 0.6
- Vincristine Sulfate Liposome Injection with Bendamustine and Rituximab as First-Line Therapy for B-Cell Lymphomas: A Phase I Study.Oncologist · 202211 citationsRCR 1.1
- Shared Local Oncology Care After Allogeneic Hematopoietic Cell Transplantation: A Randomized Clinical Trial.JAMA Oncol · 20259 citationsRCR 3.1
- 5 citationsRCR 0.5